Enterprise Value
35.27B
Cash
1.49B
Avg Qtr Burn
-121.6M
Short % of Float
4.56%
Insider Ownership
0.91%
Institutional Own.
91.80%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
TUKYSA (Tucatinib) Details Solid tumor/s, Colorectal cancer , Cancer, Metastatic colorectal cancer | Approved Quarterly sales | |
PADCEV® Details Urothelial carcinoma | Approved Quarterly sales | |
TIVDAK (tisotumab vedotin-tftv) Details Cervical cancer | Approved Quarterly sales | |
ADCETRIS® (Brentuximab Vedotin) Details Hodgkin Lymphoma | Approved Quarterly sales |